Zhuhai Livzon Diagnostics specializes in the research, development, production, and marketing of in vitro diagnostic (IVD) reagents and supporting equipment. The company has developed a range of diagnostic kits, including the Diagnostic Kit for IgM/IgG Antibody to Coronavirus (SARS-CoV-2), which utilizes a lateral flow method for rapid testing. This kit is designed to provide results within 15 minutes and can separately detect IgM and IgG antibodies, ensuring that the results do not interfere with one another. Livzon's technology platforms also include a colloidal gold method for antibody detection, a chemiluminescence detection platform, and a nucleic acid molecule detection platform, all of which support a disease-centered product system.

In addition to its diagnostic kits, Livzon Diagnostics is recognized as a high-tech enterprise with various honors, including being designated as a Guangdong New High-Tech Enterprise and a Guangdong Innovative Enterprise. The company emphasizes a commitment to quality and customer service, boasting a nationwide marketing and after-sales service network that can respond to customer inquiries and issues within 24 hours. Livzon Diagnostics is dedicated to advancing its technological capabilities and maintaining a strong focus on disease detection and management, positioning itself as a leader in the diagnostic industry in China.

China

Zhuhai Livzon DiagnosticsInc. (hereinafter referred to as “Livzon Diagnostics”) was established in 1989. It is the first high-tech subsidiary of thelisted company, Livzon Pharmaceutical Group (A-shareand H-share listed company),whospecializing in in-vitro diagnosticsin research, developing, manufacturingand marketing of diagnosis productsand automation equipment.Diagnostic Kit for IgM/IgG Antibody to Coronavirus (SARS-CoV-2) (Colloidal Gold)

Zhuhai Livzon Diagnostics

Company Details